MA43794A - Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie - Google Patents

Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie

Info

Publication number
MA43794A
MA43794A MA043794A MA43794A MA43794A MA 43794 A MA43794 A MA 43794A MA 043794 A MA043794 A MA 043794A MA 43794 A MA43794 A MA 43794A MA 43794 A MA43794 A MA 43794A
Authority
MA
Morocco
Prior art keywords
methods
immunotherapy
predicting
neoantigens
tumor
Prior art date
Application number
MA043794A
Other languages
English (en)
Other versions
MA43794B1 (fr
Inventor
Sebastian Boegel
Martin Löwer
Ugur Sahin
Barbara Schrörs
Mathias Vormehr
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biontech Rna Pharmaceuticals Gmbh, Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of MA43794A publication Critical patent/MA43794A/fr
Publication of MA43794B1 publication Critical patent/MA43794B1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in epitope analysis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5035—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on sub-cellular localization
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne des procédés de prédiction de l'utilité de peptides ou de polypeptides tels que des épitopes de lymphocytes t pour l'immunothérapie, par exemple pour la vaccination. En particulier, la présente invention concerne des procédés pour prédire si des peptides ou des polypeptides tels que des antigènes ou des épitopes associés à une tumeur, en particulier des néoantigènes ou néoépitopes associés à une tumeur, sont immunogènes et, en particulier, utiles pour l'immunothérapie, par exemple pour la vaccination. Les procédés selon l'invention peuvent être utilisés en particulier pour fournir des vaccins qui sont spécifiques d'une tumeur d'un patient et, donc, dans le contexte de vaccins anticancéreux personnalisés.
MA43794A 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie MA43794B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2016/060897 WO2017194170A1 (fr) 2016-05-13 2016-05-13 Procédés pour prédire l'utilité de protéines ou de fragments de protéines pour l'immunothérapie
PCT/EP2017/061196 WO2017194610A1 (fr) 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de protéines ou de fragments de protéines pour l'immunothérapie

Publications (2)

Publication Number Publication Date
MA43794A true MA43794A (fr) 2019-03-20
MA43794B1 MA43794B1 (fr) 2020-12-31

Family

ID=55971007

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43794A MA43794B1 (fr) 2016-05-13 2017-05-10 Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie

Country Status (27)

Country Link
US (2) US12153041B2 (fr)
EP (3) EP3792628B1 (fr)
JP (5) JP7529381B2 (fr)
KR (3) KR20240146087A (fr)
CN (1) CN109073637A (fr)
AU (2) AU2017264546B2 (fr)
BR (1) BR112018073221A2 (fr)
CA (1) CA3022654A1 (fr)
CY (1) CY1123520T1 (fr)
DK (2) DK3792628T3 (fr)
ES (2) ES2980781T3 (fr)
FI (1) FI3792628T3 (fr)
HR (2) HRP20201671T1 (fr)
HU (2) HUE052240T2 (fr)
IL (2) IL300841B1 (fr)
LT (2) LT3455625T (fr)
MA (1) MA43794B1 (fr)
MD (1) MD3455625T2 (fr)
MX (2) MX393653B (fr)
PL (2) PL3792628T3 (fr)
PT (2) PT3792628T (fr)
RS (2) RS61071B1 (fr)
SG (1) SG11201808495SA (fr)
SI (2) SI3792628T1 (fr)
SM (2) SMT202400232T1 (fr)
WO (2) WO2017194170A1 (fr)
ZA (1) ZA201805809B (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
WO2017194170A1 (fr) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Procédés pour prédire l'utilité de protéines ou de fragments de protéines pour l'immunothérapie
WO2018222433A2 (fr) 2017-05-30 2018-12-06 Nant Holdings Ip, Llc Enrichissement de cellules tumorales circulantes à l'aide de néo-épitopes
SG11202007750PA (en) * 2018-02-15 2020-09-29 National Univ Corporation Asahikawa Medical Univ Cancer antigen peptide
WO2020022897A1 (fr) 2018-07-26 2020-01-30 Frame Pharmaceuticals B.V. Procédé de préparation de compositions immunogènes spécifiques à un sujet en s'appuyant sur une base de données de néo-peptides à cadre ouvert de lecture
EP3827262A1 (fr) 2018-07-26 2021-06-02 Frame Pharmaceuticals B.V. Vaccins contre le cancer pour le cancer du sein
CN109021062B (zh) * 2018-08-06 2021-08-20 倍而达药业（苏州）有限公司 一种肿瘤新抗原的筛选方法
CN111621564B (zh) * 2019-02-28 2022-03-25 武汉大学 一种鉴定有效肿瘤新抗原的方法
KR20210137110A (ko) * 2019-03-06 2021-11-17 그릿스톤 바이오, 인코포레이티드 Mhc 클래스 ii 모델을 사용한 신생항원 동정
CN110534156B (zh) * 2019-09-02 2022-06-17 深圳市新合生物医疗科技有限公司 一种提取免疫治疗新抗原的方法及系统
CN111487399B (zh) * 2020-03-26 2021-09-17 湖南师范大学 一种蛋白分子标记在鱼类生殖细胞发育研究中的应用
WO2021205027A1 (fr) 2020-04-09 2021-10-14 Vaccibody As Vaccin anticancéreux thérapeutique individualisé
AU2021461416A1 (en) 2021-08-24 2024-02-22 BioNTech SE In vitro transcription technologies
WO2024083345A1 (fr) 2022-10-21 2024-04-25 BioNTech SE Procédés et utilisations associés à des compositions liquides
WO2025202937A1 (fr) 2024-03-26 2025-10-02 BioNTech SE Vaccins anticancéreux
WO2026159255A1 (fr) 2025-01-24 2026-07-30 BioNTech SE Technologies de détection de mutations à l'aide d'une modélisation de tumeur et d'une rétroaction

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
CN1440462A (zh) * 2000-04-28 2003-09-03 麦康公司 鉴定和生产抗原肽的方法并且将其用作疫苗
WO2002005146A2 (fr) 2000-07-10 2002-01-17 Xencor, Inc. Automatisation de conception de proteines pour la conception de bibliotheques de proteines a antigenicite modifiee
AU2002227498A1 (en) * 2000-07-31 2002-02-13 Kyogo Itoh Tumor antigen
DE10225139A1 (de) 2002-05-29 2004-02-26 Immatics Biotechnologies Gmbh Verfahren zur Identifizierung von immunreaktiven Peptiden
TW200418988A (en) * 2002-09-30 2004-10-01 Oncotherapy Science Inc Method for diagnosing prostate cancer
CA2603191A1 (fr) * 2005-03-29 2006-10-05 The Board Of Trustees Of The University Of Illinois Vaccins contre le cancer et methodes therapeutiques
JP2009273377A (ja) * 2008-05-12 2009-11-26 Igaku Seibutsugaku Kenkyusho:Kk Ｍｈｃクラスｉ分子と結合し癌細胞の表面に表出されるペプチド候補の選択方法
TW201000119A (en) * 2008-06-10 2010-01-01 Oncotherapy Science Inc MYBL2 epitope peptides and vaccines containing the same
ES2536465T3 (es) * 2008-10-01 2015-05-25 Immatics Biotechnologies Gmbh Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres
JP2012521199A (ja) 2009-03-23 2012-09-13 ウォルター アンド エリザ ホール インスティテュート オブ メディカル リサーチ 免疫応答を調節するための化合物および方法
EP2490713A2 (fr) * 2009-10-23 2012-08-29 MannKind Corporation Immunothérapie pour le cancer et procédé de traitement du cancer
WO2012159643A1 (fr) 2011-05-24 2012-11-29 Biontech Ag Vaccins individualisés pour le cancer
LT2714071T (lt) 2011-05-24 2019-10-10 Biontech Rna Pharmaceuticals Gmbh Individualizuotos vakcinos nuo vėžio
WO2012164004A1 (fr) * 2011-06-01 2012-12-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouveau peptide antigénique et ses utilisations
GB201319446D0 (en) 2013-11-04 2013-12-18 Immatics Biotechnologies Gmbh Personalized immunotherapy against several neuronal and brain tumors
JP7114477B2 (ja) 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
WO2017194170A1 (fr) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Procédés pour prédire l'utilité de protéines ou de fragments de protéines pour l'immunothérapie
AU2018254526B2 (en) 2017-04-19 2024-02-15 Seattle Project Corp. Neoantigen identification, manufacture, and use
CA3066635A1 (fr) 2017-06-09 2018-12-13 Gritstone Oncology, Inc. Identification, production et utilisation de neo-antigenes
KR102946326B1 (ko) 2017-09-05 2026-03-31 시애틀 프로젝트 코포레이션 T-세포 요법을 위한 신생항원 동정
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
IL276839B1 (en) 2018-02-27 2026-05-01 Gritstone Bio Inc Neoantigen identification using pan-allelic models

Also Published As

Publication number Publication date
KR102358620B1 (ko) 2022-02-07
EP3455625B1 (fr) 2020-09-02
SG11201808495SA (en) 2018-10-30
SI3792628T1 (sl) 2024-08-30
JP7529381B2 (ja) 2024-08-06
DK3792628T3 (da) 2024-06-17
KR20220020993A (ko) 2022-02-21
PL3792628T3 (pl) 2024-07-15
KR20240146087A (ko) 2024-10-07
US20250244311A1 (en) 2025-07-31
US12153041B2 (en) 2024-11-26
EP4411376A3 (fr) 2025-03-19
EP3792628A2 (fr) 2021-03-17
CY1123520T1 (el) 2022-03-24
WO2017194170A1 (fr) 2017-11-16
BR112018073221A2 (pt) 2019-02-19
JP2024096712A (ja) 2024-07-17
HUE067497T2 (hu) 2024-10-28
JP2019520554A (ja) 2019-07-18
ES2826480T3 (es) 2021-05-18
SMT202400232T1 (it) 2024-07-09
ES2980781T3 (es) 2024-10-03
KR20190008218A (ko) 2019-01-23
IL262680B2 (en) 2023-08-01
SMT202000622T1 (it) 2021-01-05
RS61071B1 (sr) 2020-12-31
PL3455625T3 (pl) 2021-01-25
EP4411376A2 (fr) 2024-08-07
IL262680B1 (en) 2023-04-01
WO2017194610A1 (fr) 2017-11-16
EP3455625A1 (fr) 2019-03-20
MD3455625T2 (ro) 2020-12-31
IL262680A (en) 2018-12-31
LT3455625T (lt) 2021-01-11
IL300841A (en) 2023-04-01
SI3455625T1 (sl) 2021-01-29
MX2018013081A (es) 2019-01-24
RS65568B1 (sr) 2024-06-28
CA3022654A1 (fr) 2017-11-16
LT3792628T (lt) 2024-06-25
JP2024112805A (ja) 2024-08-21
ZA201805809B (en) 2020-12-23
AU2017264546A1 (en) 2018-10-18
CN109073637A (zh) 2018-12-21
IL300841B1 (en) 2026-05-01
EP3792628B1 (fr) 2024-04-24
MA43794B1 (fr) 2020-12-31
MX2022007902A (es) 2022-07-21
JP2022081492A (ja) 2022-05-31
PT3792628T (pt) 2024-06-18
AU2017264546B2 (en) 2022-04-28
HRP20240704T1 (hr) 2024-09-27
RU2018137721A3 (fr) 2020-08-25
DK3455625T3 (da) 2020-10-26
EP3792628A3 (fr) 2021-05-19
MX393653B (es) 2025-03-24
JP2024160216A (ja) 2024-11-13
FI3792628T3 (fi) 2024-06-07
AU2022209286A1 (en) 2022-08-25
JP7888640B2 (ja) 2026-07-13
US20190178871A1 (en) 2019-06-13
HUE052240T2 (hu) 2021-04-28
HRP20201671T1 (hr) 2021-03-05
RU2018137721A (ru) 2020-06-15
PT3455625T (pt) 2020-10-22

Similar Documents

Publication Publication Date Title
MA43794B1 (fr) Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie
MX2020012130A (es) Proteinas multiespecificas de union de direccionamiento a anhidrasa carbonica 9 (caix), anoctamina-1 (ano1), mesotelina, antigeno de superficie celular de trofoblasto (trop2), antigeno carcinoembrionario (cea) o claudina-18.2.
MX2024006356A (es) Metodos para predecir la utilidad de modificaciones de aminoacidos especificas de una enfermedad para inmunoterapia
PH12018502601A1 (en) Anti-b7-h3 antibodies and antibody drug conjugates
PH12018502250A1 (en) Cancer immunotherapy by immune activation for immune modulation via globo series antigens
GT201700162A (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123
NZ750005A (en) Programmed death 1 ligand 1 (pd-l1) binding proteins and methods of use thereof
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
MX2018015285A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MX2018015277A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
CR20200434A (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (div. 5. 2018-74)
BR112018002844A2 (pt) receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
PE20191847A1 (es) Receptores de antigenos quimericos que se dirigen a flt3
MA40476A (fr) Anticorps et fragments de fixation à l'antigène anti-lag3
MA40929A (fr) Procédé de production d'anticorps à affinité élevée
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
PH12022550035A1 (en) Antibodies which bind to cancer cells and target radionuclides to said cells
MX2023009434A (es) Anticuerpos contra cd112r y usos de los mismos.
WO2023129870A3 (fr) Anticorps reconnaissant spécifiquement c5ar1 et utilisations associées
ZA202108422B (en) Anti-cd25 for tumour specific cell depletion
EA202191979A1 (ru) Композиции и способы ингибирования линиеспецифических антигенов
CR20230385A (es) Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas células
WO2021016534A3 (fr) Polypeptides antigéniques et leurs procédés d'utilisation
CR20200473A (es) PÉPTIDOS Y COMBINACIÒN DE PÉPTIDOS NOVEDOSOS PARA SU USO EN INMUNOTERAPIA CONTRA DIVERSOS TUMORES (Divisional 2017-0522)